age1’s 2024 wishlist for new companies to unlock healthy longevity for all

2023 marked a meteoric rise in the public's interest in their own longevity. Maybe not so coincidentally, 2023 was marked by the notable rise in the number of direct-to-consumer enterprises that specialize in selling supplements and offering dedicated longevity concierge services. Alongside these prominent developments, the year also witnessed remarkable progress in the longevity biotechnology sector; 2023 brought the longevity biotech field unprecedented regulatory advances, scientific advances, validation from big pharma, and an accumulation of top talent into the field. In 2023, we backed four stellar founders dedicated to improving the way we age. Our first investment, Aperture Therapeutics, is committed to curing neurodegenerative diseases and delaying brain aging through their drug discovery platform. We're equally excited about the other three ventures, which are presently in stealth mode, and we'll be sharing more about them soon. Moving into 2024, our focus remains on investi

2023 marked a meteoric rise in the public's interest in their own longevity. Maybe not so coincidentally, 2023 was marked by the notable rise in the number of direct-to-consumer enterprises that specialize in selling supplements and offering dedicated longevity concierge services. Alongside these prominent developments, the year also witnessed remarkable progress in the longevity biotechnology sector; 2023 brought the longevity biotech field unprecedented regulatory advances, scientific advances, validation from big pharma, and an accumulation of top talent into the field. In 2023, we backed f